When considering the efficacy of antitumor therapy based on complement-activating antibodies, it is reasonable to assume that the ability of complement to utilize the RIPKs and MLKL for killing or inhibiting cancer cells will be restricted to those cells that express RIPK1, RIPK3, and MLKL at sufficient levels. Here, RIPK3 is linked to cancer.